Flumatinib
Phase 2Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.Flumatinib is one of 110 small molecule programs targeting Chronic Myelogenous Leukemia. It is currently in Phase 2.
3
Indications
8
Total Trials
1
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
173 competitors in Acute Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Oncaspar
SServier
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Purinethol
SStason
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Tabloid
Akero TherapeuticsPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Myeloid Leukemia2 trials
Acute Leukemia1 trial
1 more indication
Chemotherapy1 trial
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05071482·39 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Flumatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details